Navigation Links
Nventa Biopharmaceuticals Announces Third Quarter 2008 Financial Results and Recent Corporate Highlights
Date:11/11/2008

ance may be materially different.

Forward-looking statements or information in this press release include, but are not limited to, statements or information concerning: the immunologic activity of HspE7 in treating CIN; that we identified an optimal dosing range for Phase 2 development and that our TLR3 agonist may have application in both therapeutic as well as prophylactic vaccines.

Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments to be materially different from results, events or developments expressed or implied by such forward-looking statements or information. Such factors include, among others, the possibility that immunologic activity of HspE7 may not treat CIN; the possibility that immunology responses may not be a predictor of clinical or therapeutic benefit; our need for capital; the outcomes of our clinical trials; the possibility that our drug candidate will not treat target diseases as intended; the possibility that we will not be successful in licensing our TLR3 agonist to other vaccine developers; risks associated with requirements for approvals by government agencies such as the FDA before products can be tested in clinical trials; the possibility that such government agency approvals will not be obtained in a timely manner or at all or will be conditioned in a manner that would impair our ability to advance development; risks associated with the requirement that a drug candidate be found safe and effective after extensive clinical trials; our dependence on suppliers, collaborative partners and other third parties and the prospects and timing for negotiating supply agreements, corporate collaborations or licensing arrangements; our ability to attract and retain key personnel; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at '/>"/>

SOURCE Nventa Biopharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
2. Nventa announces publication of HspE7 data
3. Nventas CEO to present at two upcoming investor conferences
4. Nventa updates progress of cervical dysplasia trial with new HspE7
5. Nventa Biopharmaceuticals Corporation announces third-quarter 2007 financial results
6. Nventa completes enrollment and initial dosing of second cohort in Phase 1 HspE7 safety trial
7. Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results
8. Nventa Appoints John Varian to Board of Directors
9. Nventa Appoints Gordon H. Busenbark to Board of Directors
10. Nventa Provides Corporate Update and Advancement Plans for HspE7, Hsp 6/11 and Poly-ICR
11. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/k6lcp2/mexico_biomedical ) ... Sensors Market - Growth, Trends & Forecasts (2014-2020)" ... Mexico Biomedical Sensors market is estimated at $0.20 billion ... period 2014-2020 The near future will bring ... of each individual. These sensors can be set to ...
(Date:8/31/2015)... 2015  RXi Pharmaceuticals Corporation (NASDAQ: RXII ... developing innovative therapies primarily in the areas of ... review period following the filing of the Company,s ... the U.S. Food and Drug Administration (FDA) has ... Logo -  http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ...
(Date:8/31/2015)... 31, 2015 Trimb Healthcare AB ("Trimb") today ... YouMedical Group BV ("YouMedical"), a Dutch OTC company with ... sales of approximately EUR 16 million, with solid growth ... "Our ambition is to build a leading international OTC ... that goal. YouMedical gives us a stronger North European ...
(Date:8/30/2015)... CHERTSEY , England , August ... Kampagne beendet die 51-jährige Wartezeit   einer Frau   ... und Frauen im Alter von 7-90   ... Programm soll 1200 Frauen behandeln und ...     , Astellas gab heute ...
Breaking Biology Technology:Mexico Biomedical Sensors Market Report 2015-2020 2RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 2RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 3RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 4Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 2Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 3Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 4Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 5
... This release is available in German . When ... light particles, so-called photons, carry sufficient energy, the electrons can be ... was explained by Einstein more than hundred years ago. Until now, ... the atom immediately after the impact of the photon. This point ...
... ... case study that provides a sustainable solution for odor and pathogen ... of beneficial microbial applications. These results are intended to address the ... who recently agreed to identify and investigate thousands of factory farms ...
... ... in Latin America regarding approvals of Stemedica’s allogeneic adult stem cell products for use in ... , ... 24, 2010 -- Stemedica Cell Technologies, Inc., a leader in allogeneic adult stem ...
Cached Biology Technology:Delayed time zero in photoemission 2Delayed time zero in photoemission 3Effective Odor and Pathogen Control in Livestock Operations Revealed in New Case Study 2Stemedica Announces the Appointment of Dr. Csar Amescua Garcia as Medical and Regulatory Affairs Director – Latin America 2
(Date:8/12/2015)... Florida , August 12, 2015 ... pace of mobile payment innovation and advanced biometrics technology ... replace the way consumers rely on using their credit ... with reinventing the future for payment services led by ... NXTD ), :  Google, Inc. (NASDAQ: GOOG ...
(Date:8/10/2015)... , August 10, 2015 ... Eye Tracking Technology for more than two decades, announces ... for integration into all consumer display formats. The SMI ... integration of eye tracking into consumer tablets, laptops, desktop ... smart glasses. Omnivision,s leading sensor technology contributes to the ...
(Date:8/6/2015)... Calif. , Aug. 6, 2015 ... developer of human interface solutions, today announced collaboration ... technologies on Windows 10. Microsoft leveraged Synaptics, deep ... the operating system. Through stringent ... are fully certified with Microsoft,s Precision TouchPad (PTP) ...
Breaking Biology News(10 mins):Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 4Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 6SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Synaptics Chosen for Human Interface Co-Development on Windows 10 2
... of continental drift provides a good model for understanding terrestrial ... successfully shed light on processes up to 3 billion years ... the earth and crust formation before that point and through ... ago. This is the conclusion of Tomas Naraa of the ...
... tissue using cells derived from the amniotic fluid is ... UCL Institute of Child Health. The paper ... cells derived from the fluids which surround the fetus ... The treatment resulted in longer survival in mice affected ...
... Inc., a Los Angeles based investment banking company, today ... Alliqua, Inc.  During the term of the engagement, WestPark ... and finance, private and public equity and debt financing, ... provide introductions to investors. About Alliqua, ...
Cached Biology News:New understanding of terrestrial formation has significant and far reaching future implications 2Potential new approach to regenerating skeletal muscle tissue 2WestPark Capital, Inc. Engaged By Alliqua, Inc. 2